JPM 2021: Boston Scientific, Abbott, Dexcom, Insulet, Silk Road Medical
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.
You may also be interested in...
The move is supported by iRhythm investors and disappointed Dexcom’s shareholders.
A trial of Insulet’s Omnipod 5 trial in children and adults showed improvements in time and range and hemoglobin A1c after three months of use compared to standard therapy.
The company expects revenues across its businesses to rapidly return to their pre-pandemic growth rates in the second half of 2021.